Premium
Microvascular changes in Down syndrome with Alzheimer's‐type pathology: Insights into a potential vascular mechanism for Down syndrome and Alzheimer's disease
Author(s) -
Drachman David A.,
Smith Thomas W.,
Alkamachi Bassam,
Kane Kevin
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.05.003
Subject(s) - pathology , alzheimer's disease , medicine , disease , down syndrome , amyloid (mycology) , psychiatry
The mechanism triggering degeneration in Alzheimer's disease (AD) remains uncertain. Therapeutic failure following amyloid β (Aβ) removal casts doubt on amyloid neurotoxicity per se as the primary cause of AD. Impaired microvascular function has been suggested as an alternative etiology. People with Down syndrome (DS) develop Alzheimer's pathology, but whether microvascular impairment also occurs in DS (as in AD) is unknown. Methods We examined brain microvasculature in five DS subjects with AD‐type histopathology, seven AD cases, and seven controls without AD‐type pathology. We counted microvessels in five anatomic regions and assessed endothelial integrity by CD31 immunohistochemistry. Results Microvascular numbers and endothelial integrity were significantly diminished in DS brains compared with controls and were similar to AD brains. Discussion People with DS and trisomy 21 produce a large amount of Aβ. If Alzheimer's pathology occurred in DS without microvascular loss or endothelial impairment, a direct neurotoxic Aβ mechanism would be supported and microvascular impairment rejected. The observation of microvascular impairment in DS with Alzheimer's disease changes fails to reject the microvascular hypothesis and provides some support for this potential mechanism of injury.